Roughly, 5.7 million people in the U.S. are living with Alzheimer’s. Globally, an estimated 47 million individuals are living with dementia. There is no cure, and treatments can only relieve certain symptoms for some people. Research studies so far have a poor record. Patients can face incredible enrollment hurdles in clinical trials.

A Patient Registry can be very useful in identifying patients. A registry can also address the original problem statement about failed trials. A robust, living registry becomes a data pool from which we can improve both drug discovery, using probabilistic statistics and AI/ML to identify new drug candidates, and drug development, using simulators to predict likelihood of success in Phase 2 or 3.

In this podcast, we discuss major challenges facing developers of Alzheimer’s therapies and address patient registries and how they can improve enrollment and trial design. In this podcast, we will hear some details about the HealthyMindsRegistry, Synexushmr.com and the Protect Study Registry, Protectstudy.org.uk registry. For US and UK citizens over 50 who have not been diagnosed with dementia can participate in the registry on-line.

Guests:

Dr Clive Ballard, Pro-Vice Chancellor and Executive Dean, University of Exeter, External partner in the AES HealthyMinds Registry (HMR)

Dr Heather Bryson, Director, Operational and Strategic Solutions at Accelerated Enrollment Solutions, (AES)

Host: Dr Julie Adams, Psychiatrist and Regional Medical Officer, PPD Biotech

Producer: Valerie Bowling, Executive Director, the Conference Forum

Alzheimer’s Studies: Exploring Registries to Improve Enrollment & Trial Design

Share

Embed